Literature DB >> 1709336

Radiation therapy for adjunctive treatment of adrenal cortical carcinoma.

A M Markoe1, W Serber, B Micaily, L W Brady.   

Abstract

Adrenocortical carcinoma is a rare disease which is primarily approached surgically. There have been few reports of the efficacy of radiation therapy and, for the most part, these have been anecdotal. This paper reports on the potential adjuvant role of radiation therapy after surgical excision of primary adrenal cortical carcinoma and also comments about the efficacy of palliative radiation therapy for metastases. We have identified eight patients treated for adrenal cortical carcinomas at Hahnemann University Hospital (HUH) from 1962 until the present and have also identified five patients with the same diagnosis at Philadelphia General Hospital (PGH) from 1962 until its close in 1975. These two groups are examined separately. In the PGH group, in which two patients were diagnosed at autopsy and only one patient was treated by radiation therapy, the median survival was between 0 and 1 month for Stage IV disease with the only patient surviving to 6 months being that patient receiving radiation therapy. In the HUH group, five of eight patients were treated adjunctively after diagnosis, one was not and two received palliative therapy. The median survival for treated Stage III patients was between 34 months and 7 years. The suggestion, based on a limited patient series, is that patients treated postoperatively to the tumor bed and nodal areas in Stage III disease may have improved survival over historic series and improved local control.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709336     DOI: 10.1097/00000421-199104000-00015

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  15 in total

Review 1.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 2.  Adrenocortical carcinoma: the management of metastatic disease.

Authors:  André P Fay; Aymen Elfiky; Gabriela H Teló; Rana R McKay; Marina Kaymakcalan; Paul L Nguyen; Anand Vaidya; Daniel T Ruan; Joaquim Bellmunt; Toni K Choueiri
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-04       Impact factor: 6.312

Review 3.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 4.  Adrenocortical carcinoma: patterns of care and role of adjuvant radiation therapy-a population-based study and review of the literature.

Authors:  S Atallah; H Al-Assaf; Y Xu; S El-Sayed
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

Review 5.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 6.  Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.

Authors:  Jens Heyn; Carolin Geiger; Christian L Hinske; Josef Briegel; Florian Weis
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 7.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

8.  Combined liver and inferior vena cava resection for adrenocortical carcinoma.

Authors:  Susumu Ohwada; Masaru Izumi; Yoshifumi Tanahashi; Susumu Kawate; Kunihiro Hamada; Hirofumi Tsutsumi; Jun Horiguchi; Yukio Koibuchi; Toru Takahashi; Masanobu Yamada
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

9.  A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.

Authors:  Mouhammed Amir Habra; Shamim Ejaz; Lei Feng; Prajnan Das; Ferhat Deniz; Elizabeth G Grubbs; Alexandria Phan; Steven G Waguespack; Montserrat Ayala-Ramirez; Camilo Jimenez; Nancy D Perrier; Jeffrey E Lee; Rena Vassilopoulou-Sellin
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

10.  Unusual cause of paraparesis in a patient with Cushing's syndrome.

Authors:  Kush Dev Jarial; Chirag K Ahuja; Soham Mukherjee; Anil Bhansali
Journal:  BMJ Case Rep       Date:  2016-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.